Improvements in the clinical signs of Parkinson’s disease using photobiomodulation: a 3-year follow-up case series

Main Article Content

Ann Liebert, PhD Brian Bicknell, PhD E-Liisa Laakso, PhD Sharon Tilley, PhD Vincent Pang, PhD Gillian Heller, PhD John Mitrofanis, PhD Geoffrey Herkes, PhD Hosen Kiat, MBBS, DMedSc

Abstract

Parkinson’s disease is a progressive neurodegenerative disease with clinical signs and symptoms that deteriorate over time. We have previously demonstrated that a combination of transcranial and remote photobiomodulation treatment has the potential to improve some clinical signs of Parkinson’s disease for up to one-year. The objective of the current study was to assess the effectiveness of continued home photobiomodulation treatment over a three-year period. Eight of the original twelve participants returned for reassessment at 2 years and six at 3 years. Participants were assessed for mobility, fine motor control, balance, and cognition. Median values for mobility and cognition continued to improve to 2 years and slightly declined to 3-years although not to pre-treatment levels. Individual participants typically improved in some outcome measures to 2-years and some participants continued to improve to 3-years. Cognition was the most sustained outcome improvement and static balance the least. Two participants who discontinued treatment after 1 year showed a decline in outcome measures. No negative side-effects of the treatment were reported. In conclusion, results suggested that at-home photobiomodulation treatment was effective to maintain improvements in clinical signs and symptoms of Parkinson’s disease for as long as treatment continued. The results of this study warrant a larger prospective randomized trial.

Keywords: Parkinson’s disease, photobiomodulation, motor symptoms, cognition, balance

Article Details

How to Cite
LIEBERT, Ann et al. Improvements in the clinical signs of Parkinson’s disease using photobiomodulation: a 3-year follow-up case series. Medical Research Archives, [S.l.], v. 11, n. 3, apr. 2023. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/3690>. Date accessed: 20 apr. 2024. doi: https://doi.org/10.18103/mra.v11i3.3690.
Section
Research Articles

References

1. Erro R, Brigo F, Tamburin S, Zamboni M, Antonini A, Tinazzi M. Nutritional habits, risk, and progression of Parkinson disease. Journal of neurology. 2018;265(1):12-23. doi: https://doi.org/10.1007/s00415-017-8639-0

2. Lang AE, Eberly S, Goetz CG, et al. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Movement Disorders. 2013;28(14):1980-1986. doi: https://doi.org/10.1002/mds.25671

3. Evans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson's disease in an incident, community based cohort. Journal of Neurology, Neurosurgery & Psychiatry. 2011;82(10):1112-1118. doi: http://dx.doi.org/10.1136/jnnp.2011.240366

4. Holden SK, Finseth T, Sillau SH, Berman BD. Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort. Movement Disorders Clinical Practice. 2018/01/01 2018;5(1):47-53. doi: https://doi.org/10.1002/mdc3.12553

5. Picillo M, LaFontant D-E, Bressman S, et al. Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease. Journal of Parkinson's Disease. 2022;12:421-436. doi:10.3233/JPD-212892

6. Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for non-motor symptoms of Parkinson's disease—an evidence‐based medicine review. Movement Disorders. 2019;34(2):180-198. doi: https://doi.org/10.1002/mds.27602

7. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. Aug 2018;33(8):1248-1266. doi: 10.1002/mds.27372

8. Lewis MM, Harkins E, Lee EY, et al. Clinical Progression of Parkinson's Disease: Insights from the NINDS Common Data Elements. J Parkinsons Dis. 2020;10(3):1075-1085. doi: 10.3233/jpd-201932

9. Salehpour F, Hamblin MR. Photobiomodulation for Parkinson’s disease in animal models: A systematic review. Biomolecules. 2020;10(4):610. doi: https://doi.org/10.3390/biom10040610

10. Tsai C. Progress of Photobiomodulation for Parkinson’s Disease. SOJ Complement Emerg Med. 2022;2(1):1-7. doi: https://doi.org/10.53902/SOJCEM.2022.02.000514

11. Liebert A, Bicknell B, Laakso EL, et al. Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study. BMC Neurology. 2021/07/02 2021;21(1):256. doi: 10.1186/s12883-021-02248-y

12. Regnault A, Boroojerdi B, Meunier J, Bani M, Morel T, Cano S. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort. Journal of Neurology. 2019/08/01 2019;266(8):1927-1936. doi:10.1007/s00415-019-09348-3

13. Bartl M, Dakna M, Schade S, et al. Longitudinal Change and Progression Indicators Using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale in Two Independent Cohorts with Early Parkinson’s Disease. Journal of Parkinson's Disease. 2022;12:437-452.
doi: 10.3233/JPD-212860

14. Chahine LM, Siderowf A, Barnes J, et al. Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures. Journal of Parkinson's Disease. 2019;9:665-679. doi: 10.3233/JPD-181518

15. Mollenhauer B, Zimmermann J, Sixel-Döring F, et al. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). Movement Disorders. 2019;34(1): 67-77. doi: https://doi.org/10.1002/mds.27492

16. Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson's disease. A prospective study. Movement disorders. 2007;22(7):938-945. doi:https://doi.org/10.1002/mds.21429

17. Helmy A, Hamid E, Salama M, Gaber A, El-Belkimy M, Shalash A. Baseline predictors of progression of Parkinson’s disease in a sample of Egyptian patients: clinical and biochemical. The Egyptian journal of neurology, psychiatry and neurosurgery. 2022;58(1):1-10. doi: https://doi.org/10.1186/s41983-022-00445-1

18. Yoo JE, Jang W, Shin DW, et al. Timed up and go test and the risk of Parkinson's disease: a nation‐wide retrospective cohort study. Movement Disorders. 2020;35(7):1263-1267. doi: https://doi.org/10.1002/mds.28055

19. Steffen T, Seney M. Test-retest reliability and minimal detectable change on balance and ambulation tests, the 36-item short-form health survey, and the unified Parkinson disease rating scale in people with parkinsonism. Physical therapy. 2008; 88(6): 733-746. doi: https://doi.org/10.2522/ptj.20070214

20. Hass CJ, Bishop M, Moscovich M, et al. Defining the clinically meaningful difference in gait speed in persons with Parkinson disease. J Neurol Phys Ther. Oct 2014;38(4):233-8. doi: 10.1097/npt.0000000000000055

21. Lidstone SC. Great Expectations: The Placebo Effect in Parkinson’s Disease. In: Benedetti F, Enck P, Frisaldi E, Schedlowski M, eds. Placebo. Springer Berlin Heidelberg; 2014:139-147.

22. Lidstone SC, Schulzer M, Dinelle K, et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Archives of general psychiatry. 2010;67(8):857 -865. doi:10.1001/archgenpsychiatry.2010.88

23. Quattrone A, Barbagallo G, Cerasa A, Stoessl AJ. Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going. Movement Disorders. 2018;33(8):1213-1227. doi: https://doi.org/10.1002/mds.27438

24. Goetz CG, Leurgans S, Raman R. Placebo-associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Movement Disorders. 2002;17(2):283-288. doi: https://doi.org/10.1002/mds.10024

25. Goetz CG, Leurgans S, Raman R, Stebbins GT. Objective changes in motor function during placebo treatment in PD. Neurology. 2000;54(3):710-710. doi: 10.1212/wnl.54.3.710

26. Goetz CG, Wuu J, McDermott MP, et al. Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions. Movement Disorders. 2008;23(5):690-699. doi: 10.1002/mds.21894

27. Allen NE, Schwarzel AK, Canning CG. Recurrent falls in Parkinson’s disease: a systematic review. Parkinson’s disease. 2013;2013. doi: https://doi.org/10.1155/2013/906274

28. Bloem BR, Grimbergen YAM, Cramer M, Willemsen M, Zwinderman AH. Prospective assessment of falls in Parkinson's disease. Journal of Neurology. 2001/11/01 2001;248 (11):950-958. doi: 10.1007/s004150170047

29. Creaby MW, Cole MH. Gait characteristics and falls in Parkinson's disease: A systematic review and meta-analysis. Parkinsonism & Related Disorders. 2018/12/01/ 2018;57:1-8. doi: https://doi.org/10.1016/j.parkreldis.2018.07.008

30. Port RJ, Rumsby M, Brown G, Harrison IF, Amjad A, Bale CJ. People with Parkinson’s Disease: What Symptoms Do They Most Want to Improve and How Does This Change with Disease Duration? Journal of Parkinson's Disease. 2021;11:715-724. doi: 10.3233/JPD-202346

31. Morris S, Morris ME, Iansek R. Reliability of measurements obtained with the Timed “Up & Go” test in people with Parkinson disease. Physical therapy. 2001;81(2):810-818. doi: https://doi.org/10.1093/ptj/81.2.810

32. Lang JT, Kassan TO, Devaney LL, Colon-Semenza C, Joseph MF. Test-Retest Reliability and Minimal Detectable Change for the 10-Meter Walk Test in Older Adults With Parkinson's disease. Journal of Geriatric Physical Therapy. 2016;39(4). doi: https://doi.org/10.1519/JPT.0000000000000068

33. Sebastia-Amat S, Tortosa-Martínez J, García-Jaén M, Pueo B. Within-subject variation in the cognitive timed up and go test as an explanatory variable in fall risk in patients with parkinson's disease. J Rehabil Med. Oct 26 2021;53(10 (October)):jrm00234. doi: 10.2340/16501977-2874

34. Çekok K, Kahraman T, Duran G, et al. Timed Up and Go Test With a Cognitive Task: Correlations With Neuropsychological Measures in People With Parkinson’s Disease. Cureus. 2020;12(9). doi: DOI: 10.7759/cureus.10604

35. Erro R, Picillo M, Vitale C, et al. The non‐motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4‐year longitudinal study. European Journal of Neurology. 2016; 23(11):1673-1679. doi: https://doi.org/10.1111/ene.13106

36. Antonini A, Barone P, Marconi R, et al. The progression of non-motor symptoms in Parkinson’s disease and their contribution to motor disability and quality of life. Journal of Neurology. 2012/12/01 2012;259(12):2621-2631. doi: 10.1007/s00415-012-6557-8

37. Biundo R, Fiorenzato E, Antonini A. Chapter Eleven - Non-motor Symptoms and Natural History of Parkinson's Disease: Evidence From Cognitive Dysfunction and Role of Noninvasive Interventions. In: Chaudhuri KR, Titova N, eds. International Review of Neurobiology. Academic Press; 2017:389-415.

38. Liebert A. Emerging applications of photobiomodulation therapy: the interaction between metabolomics and the microbiome. Photomedicine and Laser Surgery. 2018; 36(10):515-517. https://doi.org/10.1089/pho.2018.4527

39. Brown EG, Chahine LM, Goldman SM, et al. The Effect of the COVID-19 Pandemic on People with Parkinson's Disease. J Parkinsons Dis. 2020;10(4):1365-1377. doi: 10.3233/jpd-202249

40. Liebert A, Bicknell B, Laakso E-L, et al. Remote Photobiomodulation Treatment for the Clinical Signs of Parkinson's Disease: A Case Series Conducted During COVID-19. Photobiomodulation, photomedicine, and laser surgery. 2022;40(2):112-122. https://doi.org/10.1089/photob.2021.0056

41. Church FC. Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease. Biomolecules. 2021;11(4):612